High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial
Purpose - To assess the treatment outcome benefit of multiagent consolidation in young adults with acute myeloid leukemia (AML) in a prospective, randomized, multicenter trial. - Patients and Methods - Between December 2003 and November 2009, 1,179 patients (median age, 48 years; range, 16 to 60 yea...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2013
|
| In: |
Journal of clinical oncology
Year: 2013, Jahrgang: 31, Heft: 17, Pages: 2094-2102 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2012.46.4743 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.2012.46.4743 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.2012.46.4743 
|
| Verfasserangaben: | Markus Schaich, Stefani Parmentier, Michael Kramer, Thomas Illmer, Friedrich Stölzel, Christoph Röllig, Christian Thiede, Mathias Hänel, Kerstin Schäfer-Eckart, Walter Aulitzky, Hermann Einsele, Anthony D. Ho, Hubert Serve, Wolfgang E. Berdel, Jiri Mayer, Norbert Schmitz, Stefan W. Krause, Andreas Neubauer, Claudia D. Baldus, Johannes Schetelig, Martin Bornhäuser, and Gerhard Ehninger |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1788803027 | ||
| 003 | DE-627 | ||
| 005 | 20230427162751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220208s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2012.46.4743 |2 doi | |
| 035 | |a (DE-627)1788803027 | ||
| 035 | |a (DE-599)KXP1788803027 | ||
| 035 | |a (OCoLC)1341441490 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schaich, Markus |e VerfasserIn |0 (DE-588)1111909857 |0 (DE-627)865957487 |0 (DE-576)476317320 |4 aut | |
| 245 | 1 | 0 | |a High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia |b results of the prospective randomized AML2003 trial |c Markus Schaich, Stefani Parmentier, Michael Kramer, Thomas Illmer, Friedrich Stölzel, Christoph Röllig, Christian Thiede, Mathias Hänel, Kerstin Schäfer-Eckart, Walter Aulitzky, Hermann Einsele, Anthony D. Ho, Hubert Serve, Wolfgang E. Berdel, Jiri Mayer, Norbert Schmitz, Stefan W. Krause, Andreas Neubauer, Claudia D. Baldus, Johannes Schetelig, Martin Bornhäuser, and Gerhard Ehninger |
| 264 | 1 | |c 2013 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a PDF Datei enthält noch 2 Seiten Anhang | ||
| 500 | |a Gesehen am 08.02.2022 | ||
| 520 | |a Purpose - To assess the treatment outcome benefit of multiagent consolidation in young adults with acute myeloid leukemia (AML) in a prospective, randomized, multicenter trial. - Patients and Methods - Between December 2003 and November 2009, 1,179 patients (median age, 48 years; range, 16 to 60 years) with untreated AML were randomly assigned at diagnosis to receive either standard high-dose cytarabine consolidation with three cycles of 18 g/m2 (3× HD-AraC) or multiagent consolidation with two cycles of mitoxantrone (30 mg/m2) plus cytarabine (12 g/m2) and one cycle of amsacrine (500 mg/m2) plus cytarabine (10 g/m2; MAC/MAMAC/MAC). Allogeneic and autologous hematopoietic stem-cell transplantations were performed in a risk-adapted and priority-based manner. Results - After double induction therapy using a 3 + 7 regimen including standard-dose cytarabine and daunorubicin, complete remission was achieved in 65% of patients. In the primary efficacy population of patients evaluable for consolidation outcomes, consolidation with either 3× HD-AraC or MAC/MAMC/MAC did not result in any significant difference in 3-year overall (69% v 64%; P = .18) or disease-free survival (46% v 48%; P = .99) according to the intention-to-treat analysis. Furthermore, MAC/MAMAC/MAC led to additional GI and hepatic toxicity and a higher rate of infection and bleeding, resulting in significantly shorter 3-year overall survival in the per-protocol analysis compared with 3× HD-AraC (63% v 72%; P = .04). - Conclusion - In younger adults with AML, multiagent consolidation using mitoxantrone and amsacrine in combination with high-dose cytarabine does not improve treatment outcome and confers additional toxicity. | ||
| 700 | 1 | |a Parmentier, Stefani |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kramer, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Illmer, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stölzel, Friedrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Röllig, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thiede, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hänel, Mathias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schäfer-Eckart, Kerstin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aulitzky, Walter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Einsele, Hermann |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Serve, Hubert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berdel, Wolfgang E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mayer, Jiri |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmitz, Norbert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krause, Stefan W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Neubauer, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Baldus, Claudia D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schetelig, Johannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bornhäuser, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ehninger, Gerhard |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 31(2013), 17, Seite 2094-2102 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia results of the prospective randomized AML2003 trial |
| 773 | 1 | 8 | |g volume:31 |g year:2013 |g number:17 |g pages:2094-2102 |g extent:9 |a High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia results of the prospective randomized AML2003 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.2012.46.4743 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.2012.46.4743 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220208 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 12 | ||
| 999 | |a KXP-PPN1788803027 |e 4052949552 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Schaich","given":"Markus","display":"Schaich, Markus","role":"aut"},{"role":"aut","display":"Parmentier, Stefani","given":"Stefani","family":"Parmentier"},{"role":"aut","family":"Kramer","display":"Kramer, Michael","given":"Michael"},{"role":"aut","given":"Thomas","display":"Illmer, Thomas","family":"Illmer"},{"display":"Stölzel, Friedrich","given":"Friedrich","family":"Stölzel","role":"aut"},{"role":"aut","family":"Röllig","display":"Röllig, Christoph","given":"Christoph"},{"display":"Thiede, Christian","given":"Christian","family":"Thiede","role":"aut"},{"role":"aut","family":"Hänel","display":"Hänel, Mathias","given":"Mathias"},{"family":"Schäfer-Eckart","given":"Kerstin","display":"Schäfer-Eckart, Kerstin","role":"aut"},{"role":"aut","family":"Aulitzky","display":"Aulitzky, Walter","given":"Walter"},{"role":"aut","family":"Einsele","given":"Hermann","display":"Einsele, Hermann"},{"given":"Anthony Dick","display":"Ho, Anthony Dick","family":"Ho","role":"aut"},{"family":"Serve","display":"Serve, Hubert","given":"Hubert","role":"aut"},{"role":"aut","given":"Wolfgang E.","display":"Berdel, Wolfgang E.","family":"Berdel"},{"role":"aut","given":"Jiri","display":"Mayer, Jiri","family":"Mayer"},{"display":"Schmitz, Norbert","given":"Norbert","family":"Schmitz","role":"aut"},{"role":"aut","family":"Krause","given":"Stefan W.","display":"Krause, Stefan W."},{"role":"aut","display":"Neubauer, Andreas","given":"Andreas","family":"Neubauer"},{"role":"aut","family":"Baldus","given":"Claudia D.","display":"Baldus, Claudia D."},{"given":"Johannes","display":"Schetelig, Johannes","family":"Schetelig","role":"aut"},{"family":"Bornhäuser","display":"Bornhäuser, Martin","given":"Martin","role":"aut"},{"family":"Ehninger","given":"Gerhard","display":"Ehninger, Gerhard","role":"aut"}],"recId":"1788803027","origin":[{"dateIssuedDisp":"2013","dateIssuedKey":"2013"}],"name":{"displayForm":["Markus Schaich, Stefani Parmentier, Michael Kramer, Thomas Illmer, Friedrich Stölzel, Christoph Röllig, Christian Thiede, Mathias Hänel, Kerstin Schäfer-Eckart, Walter Aulitzky, Hermann Einsele, Anthony D. Ho, Hubert Serve, Wolfgang E. Berdel, Jiri Mayer, Norbert Schmitz, Stefan W. Krause, Andreas Neubauer, Claudia D. Baldus, Johannes Schetelig, Martin Bornhäuser, and Gerhard Ehninger"]},"language":["eng"],"title":[{"subtitle":"results of the prospective randomized AML2003 trial","title_sort":"High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia","title":"High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia"}],"physDesc":[{"extent":"9 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1788803027"],"doi":["10.1200/JCO.2012.46.4743"]},"relHost":[{"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"language":["eng"],"disp":"High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia results of the prospective randomized AML2003 trialJournal of clinical oncology","recId":"313116962","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1983 -"],"title":[{"title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"corporate":[{"role":"isb","display":"American Society of Clinical Oncology"}],"origin":[{"dateIssuedKey":"1983","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"part":{"extent":"9","issue":"17","year":"2013","pages":"2094-2102","text":"31(2013), 17, Seite 2094-2102","volume":"31"},"id":{"eki":["313116962"],"zdb":["2005181-5"],"issn":["1527-7755"]},"physDesc":[{"extent":"Online-Ressource"}]}],"note":["PDF Datei enthält noch 2 Seiten Anhang","Gesehen am 08.02.2022"]} | ||
| SRT | |a SCHAICHMARHIGHDOSECY2013 | ||